Caplyta Shows Promising Results In Recent Phase 3 Bipolar Trial
J&J firms up Caplyta's 1st phase 3 win in bipolar-associated manic episodes
Johnson & Johnson Announces Positive Topline Results from Pivotal Phase 3 Study Evaluating Caplyta for Treatment of Manic Episodes Associated with Bipolar I Disorder
Breaking news update. Stay tuned for more details.
Publishers
7
Articles
85
Reach
92
MDD Drug Success
New Hope for TRD
HLP003 Trial Enrollment Complete
Breakthrough MDD Drug.
MapLight Schizophrenia Drug Progress
Retatrutide's Breakthrough Obesity Results
